senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and ...

Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn ...

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...

It's not clear, but the gist of the story seems to be that Noom will be buying and repackaging Wegovy from Novo, rather than preparing and selling a generic semaglutide concoction of its own.

Moreover, Novo is advancing with new GLP-1 agonist formulations for both diabetes and obesity, which are much further along than what Lilly presented in its announcement. Oral semaglutide ...

and Ozempic (semaglutide) for weight loss and type 2 diabetes, respectively, reached DKr73.5bn. Novo Nordisk stated that obesity sales were the main driver – up 65% compared to Q1 2024.

Novo Nordisk abstracts to be presented, some of these data for semaglutide are investigational: Predicting weight loss using self-reported, digitally collected, real-world data after initiation of ...

Image: Adobe Stock Using the Eversana Life Sciences electronic health record dataset, the researchers identified 92,405 patients with obesity treated with semaglutide (Ozempic/Wegovy, Novo Nordisk ...

How Does Semaglutide Work for Weight Loss ... A 2021 study funded by Novo Nordisk (the manufacturer of Ozempic, Wegovy, and Rybelsus) looked at almost 2,000 people with excess weight or obesity ...

MÁLAGA, Spain — Semaglutide (Wegovy ... The SELECT trial was funded by Novo Nordisk. Ryan reported receiving consulting honoraria from companies including AbbVie, Amgen, AstraZeneca, Biohaven ...